Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
| Autor: | Hanne Haahr, Tim Heise, Kadriye Kaplan, Marianne Nørskov, Susanne Famulla, Leszek Nosek |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Insulin degludec
medicine.medical_specialty type 1 diabetes insulin analogues Endocrinology Diabetes and Metabolism Insulin Glargine 030209 endocrinology & metabolism 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Endocrinology Animal science Internal medicine pharmacodynamics Internal Medicine medicine Humans Hypoglycemic Agents Potency Dosing Type 1 diabetes Insulin glargine business.industry Original Articles medicine.disease Crossover study Confidence interval Insulin Long-Acting Diabetes Mellitus Type 1 insulin therapy Pharmacodynamics Original Article business medicine.drug |
| Zdroj: | Diabetes, Obesity & Metabolism |
| ISSN: | 1462-8902 |
| Popis: | Aim To compare day-to-day and within-day variability in glucose-lowering effect between insulin degludec (IDeg) and insulin glargine 300 U/mL (IGlar-U300) in type 1 diabetes. Materials and methods In this double-blind, crossover study, patients were randomly assigned to 0.4 U/kg of IDeg or IGlar-U300 once daily for two treatment periods lasting 12 days each. Pharmacodynamic variables were assessed at steady-state from the glucose infusion rate profiles of three 24-hour euglycaemic glucose clamps (days 6, 9 and 12) during each treatment period. Results Overall, 57 patients completed both treatment periods (342 clamps). The potency of IGlar-U300 was 30% lower than IDeg (estimated ratio 0.70, 95% confidence interval [CI] 0.61; 0.80; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text